Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Gastrointestinal, Microbiota Balance, Microbiota, Cortisol, Butyrate, Bloating, Gastrointestinal Upset, Immuno-modulation
Interventions: Postbiotic; Dietary Supplement
Lead sponsor: Verb Biotics LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Canfield, Ohio

Conditions: Cystic Fibrosis
Interventions: VX-809, Placebo, VX-770; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 26 more

Conditions: Congenital Heart Defects
Interventions: Triostat, Placebo; Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: Up to 5 Months
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 3
States / cities: Los Angeles, California • Palo Alto, California • Seattle, Washington

Conditions: Heart Failure With Reduced Ejection Fraction, Dilated Cardiomyopathy
Interventions: MYK-491, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 9
States / cities: Jacksonville, Florida • Saint Paul, Minnesota • St Louis, Missouri + 6 more

Conditions: Healthy
Interventions: Lasmiditan, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 2
States / cities: Daytona Beach, Florida • Evansville, Indiana

Conditions: Osteoarthritis, Articular Cartilage, Musculoskeletal Disorders
Interventions: Platelet-Rich Plasma (PRP) Injections, Centrifuge, Control saline injection; Drug · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Atopic Dermatitis
Interventions: REGN3500, REGN3500-Matching Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 31
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more

Conditions: Aggression, Post Traumatic Stress Disorders
Interventions: Strength at Home Couples Group, Supportive Group Therapy; Behavioral
Lead sponsor: Boston VA Research Institute, Inc.; Other
Eligibility: 18 Years to 60 Years
Enrollment: 156 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts • Providence, Rhode Island

Conditions: Multiple Sclerosis
Interventions: ketamine; Drug
Lead sponsor: Alta Bates Summit Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Thyroid Disease, Kidney Diseases, Chronic
Interventions: Levothyroxine Sodium, Placebo Oral Tablet; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Orange, California

Conditions: Actinic Cheilitis, Squamous Cell Carcinoma In-situ (SCC-is), Squamous Cell Carcinoma (SCC), Photodynamic Therapy (PDT), Mohs Surgery
Interventions: PDT prior to Mohs surgery; Procedure
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Allergy
Interventions: REGN1908-1909, placebo; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Overland Park, Kansas • Baltimore, Maryland

Conditions: RSV Infection
Interventions: Obeldesivir, Obeldesivir Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: Up to 5 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 41
States / cities: Birmingham, Alabama • Oneonta, Alabama • Phoenix, Arizona + 33 more

Conditions: Atherosclerosis
Interventions: LS followed by NS diet condition, NS followed by LS diet condition, Placebo, RO6836191; Other · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Marlton, New Jersey

Conditions: Graft-versus-host-disease, Ocular Graft-versus-host Disease
Interventions: Lifitegrast 5% Ophthalmic Solution, Placebo; Drug
Lead sponsor: Richard W Yee, MD; Other
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Bellaire, Texas

Conditions: Pain
Interventions: Music therapy, Sucrose; Other
Lead sponsor: New York City Health and Hospitals Corporation; Other
Eligibility: 37 Weeks to 42 Weeks
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: HIV/AIDS-associated Fatigue
Interventions: American ginseng, Placebo for American ginseng; Drug · Dietary Supplement
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pain
Interventions: lidocaine-prilocaine cream, Placebo cream; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: HIV Infection, HIV Infections
Interventions: Losartan, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Severe Bronchopulmonary Dysplasia
Interventions: Albuterol Sulfate, Sterile Saline; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 1 Year
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Urticaria
Interventions: GDC-0853, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 13
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 10 more

Conditions: Infections, Respiratory Tract
Interventions: GSK1325756 Solution, GSK1325756 Solution Matching Placebo, GSK1325756 Tablet, GSK1325756 Tablet Matching Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: AZD5099, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy
Interventions: IVX-A12, Placebo; Biological
Lead sponsor: Icosavax, Inc.; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 264 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 10
States / cities: Tempe, Arizona • Hollywood, Florida • Stockbridge, Georgia + 7 more

Search by objective public record fields.

The Effects of a Postbiotic Supplement on Biomarkers of Gut Health

A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation

Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass

v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491

A Study of Lasmiditan in Healthy Participants

Platelet Rich Plasma Injections In Young And Old Human Subjects

Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Strength at Home Couples Program (PTSD-Focused Relationship Enhancement Therapy for Returning Veterans)

Ketamine for MS Fatigue

A Pilot Feasibility Trial of Thyroid Hormone Replacement in Dialysis Patients

Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip

Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects

Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection

A Single Ascending Dose Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of RO6836191 in Healthy Male Volunteers.

The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease

Music Therapy for Pain Management for Minor Procedures in Neonates.

American Ginseng to Improve HIV-Associated Fatigue: A Randomized, Placebo-Controlled, Parallel Design, Multiple-Dose Clinical Trial

Topical Anesthetic Use In Pessary Management

Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV

Aerosolized Albuterol Use in Severe BPD

A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects

Clinical Study Assessing the Safety, Tolerability, and Pharmacokinetics of Intravenous AZD5099 in Healthy Subjects

A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age